CCMG
SLNO

Clark Capital Management Group’s Soleno Therapeutics SLNO Stock Holding History

Clark Capital Management Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-180,250
Closed -$8.35M – 552
2025
Q4 		$8.35M Buy
+180,250
New +$9.88M 0.05% 182

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Clark Capital Management Group's SLNO Position: Q1 2026 in Review

Clark Capital Management Group sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 180,250 shares — an estimated $8.35M sold.

Clark Capital Management Group first reported a position in SLNO in Q4 2025 and held it in 1 quarter. The position peaked at $8.35M in Q4 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Clark Capital Management Group reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Clark Capital Management Group sold 180,250 Soleno Therapeutics shares in Q1 2026, an estimated $8.35M.
  • Clark Capital Management Group first reported a position in Soleno Therapeutics in Q4 2025 and held it in 1 quarter.
  • Clark Capital Management Group's Soleno Therapeutics position peaked at $8.35M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Clark Capital Management Group's 13F filing for Q1 2026, filed 15 May 2026.